A Ground Breaking Approach to Cure Cancer
BioConvergent Health (BCH) has pioneered a proprietary, BioConvergent approach using drug + energy device therapies (e.g., radiation and/or ultrasound) to train the patient’s immune system to kill metastatic cancer while maintaining a high quality of life.
Current State of Metastatic Cancer Treatment
The lack of effective and well tolerated treatment options for metastatic cancers leads to treatment failures, high mortality rate, and terrible quality of life.
Chemotherapy kills all cells causing toxicity and tumors become resistant.
Immunotherapies eventually lose their effect on the immune response.
Targeted therapies kill cells selectively, but there is an issue with tumor accessibility and tumor resistance.
Radiation is only used palliatively and for local control.
BioConvergent Health
Solutions to Enhance
Patient Outcomes
Our platform is based on core patented assets licensed from leading pharmaceutical companies, device companies, and academic medical institutions (with greater than $400M invested to date). We have a breakthrough proprietary approach using drug(s) + energy (e.g., radiation and ultrasound) to train the patient’s immune system to kill metastatic cancers while maintaining a high quality of life. We have patients with durable remissions who had treatment-resistant metastatic cancer in a Phase 2 study using this approach. We can use existing blockbuster therapies with our platform to improve their efficacy and safety and extend their patent life.
Our Pipeline
Oncology
Lead Indication:
Non-small Cell Lung Cancer (NSCLC)
Product
Drug X + Radiation
